Skip to main content

Mitochondrial Disorders: Biochemical and Molecular Basis of Disease

Cover image for Research Topic "Mitochondrial Disorders: Biochemical and Molecular Basis of Disease"
109kviews
Editorial19 November 2021
Editorial: Mitochondrial Disorders: Biochemical and Molecular Basis of Disease

Mitochondria are dynamic, double-membrane organelles that play an essential function in cellular energy metabolism, in which the citric acid cycle, fatty acid β-oxidation and oxidative phosphorylation act in concert to generate most of the ATP in cells. However, in the last decades, mitochondria have been reported to execute and regulate many other functions, including ATP production, metabolism of amino acids, lipids and nucleotides, iron-sulfur cluster synthesis, calcium homeostasis, and programmed cell death. Healthy mitochondria take up calcium not only to regulate their own intrinsic metabolism and stimulate the production of ATP, but also to buffer cytosolic calcium rises that occur during normal cell functioning (Dard et al., 2020). However, calcium influx beyond the buffering capacity of mitochondria, as well as reactive oxygen overproduction trigger mitochondrial permeability transition that may cause apoptosis (Vercesi et al., 2018).

For maintenance of normal mitochondrial functionality, this organelle depends on a delicate balance between fission and fusion (mitochondrial dynamics). The fusion and fission cycle consists, respectively, of the formation of an elongated organelle by fusing two or more mitochondria and by the division of one mitochondrion into two daughter mitochondria (Tilokani et al., 2018). While mitofusins 1 and 2 and optic atrophy 1 protein mediate fusion of the outer and inner mitochondrial membrane, correspondingly, dynamin-related protein 1 is considered a crucial player in the fission process, forming oligomers around mitochondria to constrict them (Tilokani et al., 2018).

The pivotal role of mitochondria for cellular survival is highlighted by the variety of diseases that are associated with mitochondrial dysfunction. In this sense, mitochondrial inherited genetic disorders, which may be caused either by mutations in nuclear genes or mitochondrial DNA encoding mitochondrial proteins, usually affect multiple tissues, typically those which are highly dependent on aerobic metabolism (Gorman et al., 2016; Ferreira and van Karnebee, 2019; Wajner, 2019). While primary defects are characterized by disturbances in oxidative phosphorylation and other energy generating pathways, secondary mitochondrial diseases result from the toxic influences of endogenous metabolites to the mitochondria and/or cell physiology in general. In this topic “Mitochondrial Disorders: Biochemical and Molecular Basis of Disease”, we provide a collection of nine articles covering diverse aspects of primary and secondary mitochondrial disorders.

The pathophysiology of mitochondrial disorders is the main theme of two articles. Amaral and Wajner (2020) review the toxic effects of fatty acids accumulating in fatty acid oxidation disorders causing impairment of mitochondrial bioenergetics and calcium homeostasis and inducing permeability transition pore opening. The group of Dr. Schwarz (Mellis et al., 2021) shows alterations of mitochondrial dynamics in embryonic fibroblasts prepared from Suox-/- mice (isolated sulfite oxidase deficiency model) and fibroblasts from patients with molybdenum cofactor deficiency (MOCS1A, MOCCS1B, MOCS2, and GPHN genes), indicating that disturbances in the mitochondrial network are involved in the pathophysiology of these disorders.

The elucidation of the reaction mechanism of mitochondrial enzymes may help to understand the biochemical abnormalities associated with mitochondrial disorders. In this regard, the article by Leung et al. (2021) provides evidence that glycine cleavage system H protein (GCSH) has an additional role beyond being a component of the glycine cleavage system, a protein complex that decarboxylates glycine. The study demonstrates that loss of GCSH causes embryonic death of homozygous Gcsh null mice, unlike animals with a deficiency of the other proteins belonging to glycine cleavage system, which are compatible with embryonic survival. Furthermore, Cronan (2020) reviews the reaction mechanism of lipoic acid metabolism enzymes with the aim to better understand the biochemistry and physiology of mitochondrial disorders that affect the assembly of this coenzyme on its cognate enzyme proteins.

In addition, different models for mitochondrial disease research are reviewed by the group of Dr. Sánchez-Alcázar (Povea-Cabello et al., 2021), with emphasis on direct cellular reprogramming. Another article by Schlieben and Prokisch (2020) gives an overview of the mitochondrial disease associated genes, with focus on the classification of these disorders according to the functional roles of deficient proteins, with implications for diagnosis. This topic also includes a perspective article on the outcome of triheptanoin in treating long chain fatty acid oxidation disorders, with special emphasis on the cardiomyopathy and hypoglycemia observed in affected patients (Sklirou et al., 2021).

Finally, two articles present case reports of primary mitochondrial disorders. Kusikova et al. (2021) give a brief review on the mitochondrial disorder caused by mutations in VARS2, which encodes the mitochondrial valyl-tRNA synthetase, and presents a patient with a new missense biallelic variant leading to a novel phenotypic presentation. Moreover, Yan et al. (2021) report the first three Chinese cases of combined oxidative phosphorylation deficiency 23 (COXPD23), which is caused by mutations in GTPBP3, as well as genotype-phenotype correlations of these patients.

In conclusion, this topic provides a valuable collection of articles revealing important aspects of the genetic and biochemical basis and pathophysiology of mitochondrial disorders. While most articles emphasize bioenergetic dysfunction as a fundamental mechanism in mitochondrial disorders, this topic also explores the involvement of other mitochondrial functions and processes that are impaired in these pathologies, such as calcium homeostasis, mitochondrial dynamics and permeability transition. We hope that the articles presented here stimulate future studies not only focused on the expansion of current knowledge but also on the development of novel adjuvant therapeutic strategies with the aim to provide new treatment options and/or to prevent these devastating conditions.

2,761 views

1 citations

ORIGINAL RESEARCH
1 July 2021
Novel Mutations in the GTPBP3 Gene for Mitochondrial Disease and Characteristics of Related Phenotypic Spectrum: The First Three Cases From China
Hui-ming Yan, 8 more and Hua Wang

4,925 views

15 citations

PERSPECTIVE
15 January 2021
Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders
Evgenia Sklirou, 3 more and Jerry Vockley
Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders
Inborn errors of mitochondrial fatty acid oxidation (FAO) comprise the most common group of disorders identified through expanded newborn screening mandated in all 50 states in the US, affecting 1:10,000 newborns. While some of the morbidity in FAO disorders (FAODs) can be reduced if identified through screening, a significant gap remains between the ability to diagnose these disorders and the ability to treat them. At least 25 enzymes and specific transport proteins are responsible for carrying out the steps of mitochondrial fatty acid metabolism, with at least 22 associated genetic disorders. Common symptoms in long chain FAODs (LC-FAODs) in the first week of life include cardiac arrhythmias, hypoglycemia, and sudden death. Symptoms later in infancy and early childhood may relate to the liver or cardiac or skeletal muscle dysfunction, and include fasting or stress-related hypoketotic hypoglycemia or Reye-like syndrome, conduction abnormalities, arrhythmias, dilated or hypertrophic cardiomyopathy, and muscle weakness or fasting- and exercise-induced rhabdomyolysis. In adolescent or adult-onset disease, muscular symptoms, including rhabdomyolysis, and cardiomyopathy predominate. Unfortunately, progress in developing better therapeutic strategies has been slow and incremental. Supplementation with medium chain triglyceride (MCT; most often a mixture of C8-12 fatty acids containing triglycerides) oil provides a fat source that can be utilized by patients with long chain defects, but does not eliminate symptoms. Three mitochondrial metabolic pathways are required for efficient energy production in eukaryotic cells: oxidative phosphorylation (OXPHOS), FAO, and the tricarboxylic (TCA) cycle, also called the Krebs cycle. Cell and mouse studies have identified a deficiency in TCA cycle intermediates in LC-FAODs, thought to be due to a depletion of odd chain carbon compounds in patients treated with a predominantly MCT fat source. Triheptanoin (triheptanoylglycerol; UX007, Ultragenyx Pharmaceuticals) is chemically composed of three heptanoate (seven carbon fatty acid) molecules linked to glycerol through ester bonds that has the potential to replete TCA cycle intermediates through production of both acetyl-CoA and propionyl-CoA through medium chain FAO. Compassionate use, retrospective, and recently completed prospective studies demonstrate significant reduction of hypoglycemic events and improved cardiac function in LC-FAOD patients, but a less dramatic effect on muscle symptoms.

10,688 views

41 citations

ORIGINAL RESEARCH
7 January 2021
Sulfite Alters the Mitochondrial Network in Molybdenum Cofactor Deficiency
Anna-Theresa Mellis, 3 more and Guenter Schwarz

7,069 views

25 citations

REVIEW
12 January 2021
Advances in mt-tRNA Mutation-Caused Mitochondrial Disease Modeling: Patients’ Brain in a Dish
Suleva Povea-Cabello, 7 more and José A. Sánchez-Alcázar

9,488 views

13 citations

The concept of a mitochondrial disorder was initially described in 1962, in a patient with altered energy metabolism. Over time, mitochondrial energy metabolism has been discovered to be influenced by a vast number of proteins with a multitude of functional roles. Amongst these, defective oxidative phosphorylation arose as the hallmark of mitochondrial disorders. In the premolecular era, the diagnosis of mitochondrial disease was dependent on biochemical criteria, with inherent limitations such as tissue availability and specificity, preanalytical and analytical artefacts, and secondary effects. With the identification of the first mitochondrial disease-causing mutations, the genetic complexity of mitochondrial disorders began to unravel. Mitochondrial dysfunctions can be caused by pathogenic variants in genes encoded by the mitochondrial DNA or the nuclear DNA, and can display heterogenous phenotypic manifestations. The application of next generation sequencing methodologies in diagnostics is proving to be pivotal in finding the molecular diagnosis and has been instrumental in the discovery of a growing list of novel mitochondrial disease genes. In the molecular era, the diagnosis of a mitochondrial disorder, suspected on clinical grounds, is increasingly based on variant detection and associated statistical support, while invasive biopsies and biochemical assays are conducted to an ever-decreasing extent. At present, there is no uniform biochemical or molecular definition for the designation of a disease as a “mitochondrial disorder”. Such designation is currently dependent on the criteria applied, which may encompass clinical, genetic, biochemical, functional, and/or mitochondrial protein localization criteria. Given this variation, numerous gene lists emerge, ranging from 270 to over 400 proposed mitochondrial disease genes. Herein we provide an overview of the mitochondrial disease associated genes and their accompanying challenges.

17,415 views

107 citations

REVIEW
27 November 2020
Recent Advances in the Pathophysiology of Fatty Acid Oxidation Defects: Secondary Alterations of Bioenergetics and Mitochondrial Calcium Homeostasis Caused by the Accumulating Fatty Acids
Alexandre Umpierrez Amaral and Moacir Wajner

11,194 views

26 citations